Stirling A (2007) Risk, precaution and science: towards a more constructive policy debate. *EMBO Rep* **8**: 309–315

Wiedemann PM, Schütz H (2005) The precautionary principle and risk perception: experimental studies in the EMF area. *Environ Health Perspect* **113**: 402–405

Wiedemann PM, Thalmann AT, Grutsch MA, Schütz H (2006) The impacts of precautionary measures and the disclosure of scientific uncertainty on EMF risk perception and trust. *J Risk Res* **9**: 361–372

Holger Schütz & Peter Wiedemann are in the Programme Group MUT at Research Centre Jülich, Germany

E-mail: h.schuetz@fz-juelich.de

E-mail: p.wiedemann@fz-juelich.de

Martin Clauberg is in the Department of Civil & Environmental Engineering and the Institute for Environmental Modelling, University of Tennessee, Oak Ridge, Tennessee, USA

E-mail: clauberg@utk.edu

doi:10.1038/sj.embor.7401019

Proper science in moist biology

Last year, Geoffrey Chang and co-workers retracted five papers that contained a faulty protein structure prediction—the result of an error in their software (Chang *et al*, 2006). Although the ensuing debates and arguments about this ‘great pentaretraction’ have slowly dissipated, it is useful to shed some light on the context in which such mistakes occur. We believe that there are fundamental differences in the scientific philosophy and methodology underlying the discussion that cannot and should not be explained by current definitions of good or bad science. This is not exclusive to protein crystallography; it is also typical of other large-scale, high-tech research fields including nanotechnology, systems biology and imaging technologies.

In general, structural biology is a ‘hot’ research field, involving the constant development of analytical approaches and technologies—combinations of two specific styles of science (Hacking, 1992): classical ‘wet’ bench work, and ‘dry’ computational and mathematical work.

Each style of science—wet and dry—represents a framework for getting at the truth, and comes with its own scientific method, distinct protocols, technologies, theories, language and more general ‘ways

of doing’. Consequently, it is possible to make claims within one style that make no sense from the viewpoint of the other. For example, the claim that “MsbA is a member of the MDR–ABC transporter group by sequence homology” (Chang & Roth, 2001) is the result of an *in silico* comparison of sequences that can neither be performed at the bench, nor understood or proven by wet work alone.

This implies that wet and dry science differ in terms of what their proponents regard as ‘proper science’. In an article in *Science*, Chris Miller, from the Howard Hughes Medical Institute (Waltham, MA, USA), wrote that structures are “just models, not data” and argued that the danger lies in “ignoring biochemical results, conventional but logically solid” (Miller, 2007). He was clearly commenting on the pentaretraction from a wet point of view. From a dry perspective, comments about the error were generally less harsh. It is a widely accepted practice—necessary for doing dry science—to trust a model or an algorithm and believe the outcome. Consequently, dry scientists have generally attributed the error resulting in the Chang retractions to bad luck, an honest mistake, or ‘much ado about nothing’. Conversely, the wet community has tended to use more harsh terms including: debacle, fiasco, monumental blunder, sloppy science and inexcusable.

In scientific fields such as structural biology, wet and dry styles are becoming increasingly interdependent. As the complexity of their data far exceeds the computing ability of the human mind, scientists have no choice but to trust computer models. This interaction has become commonplace to a level at which claims, technologies and tools are no longer either wet or dry. They can only be understood and used within a new framework or style that we call ‘moist’ science—an integration of dry and wet styles. Accordingly, moist science creates a new way of doing ‘proper science’. Critiques directed at Chang and co-workers exclusively from a dry or a wet point of view therefore cannot fully evaluate the ‘properness’ of their research, or fully assess the magnitude of any mistakes.

As moist science is a science in the making, some of its technologies are still experimental and protocols have not yet been unanimously accepted. The specific criteria for what it deems to be ‘proper science’, or what exactly counts as a mistake, have not yet been set. For example, should the code

of an algorithm—which in this case created the error—be included in the methods section of a publication, or made available as supplementary material online? This and other questions must be settled in order to reach a new consensus on what constitutes ‘proper science’. Therefore, the lesson is not whether to blame, but how to learn from and improve on this new moist scientific style.

REFERENCES

- Chang G, Roth CB (2001) Structure of MsbA from *E. coli*: A homolog of the multidrug resistance ATP binding cassette (ABC) transporters. *Science* **293**: 1793–1800
- Chang G, Roth CB, Reyes CL, Pornillos O, Chen YJ, Chen AP (2006) Retraction. *Science* **314**: 1875
- Hacking I (1992) ‘Style’ for historians and philosophers of science. *Stud Hist Philos Sci* **23**: 1–20
- Miller C (2007) Pretty structures, but what about the data? *Science* **315**: 459

Bart Penders, Klasien Horstman & Rein Vos are at the Department of Health, Ethics & Society, Maastricht University, Maastricht, the Netherlands.

E-mail: b.penders@zw.unimaas.nl

doi:10.1038/sj.embor.7401020

Philanthropy in Portugal

At the European Council meeting in Lisbon in 2000, the European Union (EU) established the strategic goal of becoming “the most dynamic and competitive knowledge-based economy in the world” by 2010 (Fontaine, 2000). To achieve this, each EU member state would be required to increase its investment in research and development (R&D) to 3% of its Gross Domestic Product (GDP), which would necessitate an increase in both public and private investments.

An important component of private investment is philanthropy. A group of experts recently proposed several policy recommendations to strengthen the role of philanthropy in financing R&D in Europe (EC, 2005). Their report concluded that the EU must further exploit the potential of philanthropy to achieve the strategic investment goals established in the Lisbon Agenda (EC, 2006a).

However, many European societies do not have a well-established philanthropic framework. This is in contrast to the USA and Canada, which have strong philanthropic